Clinical Research Directory

Inclusion Criteria: Each patient must meet all of the following inclusion criteria for study enrollment: * Age ≥18 with ability to provide written informed consent * Pathologically confirmed WHO Grade IV Gliobastoma prior receiving radiotherapy * Prior radiotherapy to a dose of ≥50Gy * No signs of distant metastases * Baseline laboratory assessment including CBC and blood chemistry, ANC \> or equal 1500, Platelet count greater or equal 100. Liver function tests and creatinine not greater than twice ULN. * Patient should not be pregnant. Urine or blood β-HCG within 14 days prior to study start for females who are not atleast one year post-menopausal or who have ot undergone a surgical sterilization procedure * A baseline MRI scan of the brain is required to determine how much tumor is present for properly planning patient's radiotherapy. * Karnofsky Performance Status (KPS) below 60 or ECOG of 3 or 4 * Any number or type of prior chemotherapy is allowed (patient may receive concurrent or adjuvant systemic therapy such as cetuximab at the discretion of the treating oncologic team). Exclusion Criteria: Patients meeting any of the following exclusion criteria are not eligible for enrollment: * Evidence of distant metastases on any staging or imaging modality * Women who are breast feeding, or have a positive pregnancy test (reproductive age should use effective birth control during study) * Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the principal investigator. * Karnofsky Performance Status less than 50 * Prior radiotherapy to involved site in brain.